ID   PYRD_HUMAN              Reviewed;         395 AA.
AC   Q02127; A8K8C8; Q6P176;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 3.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Dihydroorotate dehydrogenase (quinone), mitochondrial;
DE            Short=DHOdehase;
DE            EC=1.3.5.2;
DE   AltName: Full=Dihydroorotate oxidase;
DE   Flags: Precursor;
GN   Name=DHODH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-7.
RX   PubMed=1446837; DOI=10.1016/0378-1119(92)90150-N;
RA   Minet M., Dufour M.E., Lacroute F.;
RT   "Cloning and sequencing of a human cDNA coding for dihydroorotate
RT   dehydrogenase by complementation of the corresponding yeast mutant.";
RL   Gene 121:393-396(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   PubMed=7487077; DOI=10.1006/abbi.1995.0012;
RA   Copeland R.A., Davis J.P., Dowling R.L., Lombardo D., Murphy K.B.,
RA   Patterson T.A.;
RT   "Recombinant human dihydroorotate dehydrogenase: expression,
RT   purification, and characterization of a catalytically functional
RT   truncated enzyme.";
RL   Arch. Biochem. Biophys. 323:79-86(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-7.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   ENZYME ACTIVITY.
RX   PubMed=8925840; DOI=10.1111/j.1432-1033.1996.0292h.x;
RA   Knecht W., Bergjohann U., Gonski S., Kirschbaum B., Loeffler M.;
RT   "Functional expression of a fragment of human dihydroorotate
RT   dehydrogenase by means of the baculovirus expression vector system,
RT   and kinetic investigation of the purified recombinant enzyme.";
RL   Eur. J. Biochem. 240:292-301(1996).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10727948; DOI=10.1046/j.1432-1327.2000.01213.x;
RA   Rawls J., Knecht W., Diekert K., Lill R., Loeffler M.;
RT   "Requirements for the mitochondrial import and localization of
RT   dihydroorotate dehydrogenase.";
RL   Eur. J. Biochem. 267:2079-2087(2000).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 29-395 IN COMPLEX WITH FMN;
RP   DIHYDROOROTATE AND INHIBITORS, AND COFACTOR.
RX   PubMed=10673429; DOI=10.1016/S0969-2126(00)00077-0;
RA   Liu S., Neidhardt E.A., Grossman T.H., Ocain T., Clardy J.;
RT   "Structures of human dihydroorotate dehydrogenase in complex with
RT   antiproliferative agents.";
RL   Structure 8:25-33(2000).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 29-395 IN COMPLEX WITH FMN
RP   AND INHIBITORS.
RX   PubMed=16480261; DOI=10.1021/jm0506975;
RA   Baumgartner R., Walloschek M., Kralik M., Gotschlich A., Tasler S.,
RA   Mies J., Leban J.;
RT   "Dual binding mode of a novel series of DHODH inhibitors.";
RL   J. Med. Chem. 49:1239-1247(2006).
RN   [12]
RP   VARIANTS POADS GLU-19; CYS-135; ARG-152; CYS-199; ALA-202; ASP-202;
RP   TRP-244; ILE-284; TRP-346 AND GLY-392.
RX   PubMed=19915526; DOI=10.1038/ng.499;
RA   Ng S.B., Buckingham K.J., Lee C., Bigham A.W., Tabor H.K., Dent K.M.,
RA   Huff C.D., Shannon P.T., Jabs E.W., Nickerson D.A., Shendure J.,
RA   Bamshad M.J.;
RT   "Exome sequencing identifies the cause of a Mendelian disorder.";
RL   Nat. Genet. 42:30-35(2010).
CC   -!- FUNCTION: Catalyzes the conversion of dihydroorotate to orotate
CC       with quinone as electron acceptor.
CC   -!- CATALYTIC ACTIVITY: (S)-dihydroorotate + a quinone = orotate + a
CC       quinol. {ECO:0000269|PubMed:8925840}.
CC   -!- COFACTOR:
CC       Name=FMN; Xref=ChEBI:CHEBI:58210;
CC         Evidence={ECO:0000269|PubMed:10673429};
CC       Note=Binds 1 FMN per subunit. {ECO:0000269|PubMed:10673429};
CC   -!- PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo
CC       pathway; orotate from (S)-dihydroorotate (quinone route): step
CC       1/1.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:10673429,
CC       ECO:0000269|PubMed:16480261}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:10727948}; Single-pass membrane protein
CC       {ECO:0000269|PubMed:10727948}.
CC   -!- PTM: The uncleaved transit peptide is required for mitochondrial
CC       targeting and proper membrane integration.
CC   -!- DISEASE: Postaxial acrofacial dysostosis (POADS) [MIM:263750]:
CC       POADS is characterized by severe micrognathia, cleft lip and/or
CC       palate, hypoplasia or aplasia of the posterior elements of the
CC       limbs, coloboma of the eyelids and supernumerary nipples. POADS is
CC       a very rare disorder: only 2 multiplex families, each consisting
CC       of 2 affected siblings born to unaffected, nonconsanguineous
CC       parents, have been described among a total of around 30 reported
CC       cases. {ECO:0000269|PubMed:19915526}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The identification of DHODH defects as the cause of
CC       postaxial acrofacial dysostosis (POADS) was obtained via exome
CC       sequencing (PubMed:19915526), demonstrating that this method is a
CC       powerful tool for identifying genes underlying rare Mendelian
CC       disorders. Exome sequencing consists of targeted resequencing of
CC       all protein-coding subsequences, which requires around 5% as much
CC       sequencing as a whole human genome. {ECO:0000305|PubMed:19915526}.
CC   -!- SIMILARITY: Belongs to the dihydroorotate dehydrogenase family.
CC       Type 2 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M94065; AAA50163.1; -; mRNA.
DR   EMBL; AK292293; BAF84982.1; -; mRNA.
DR   EMBL; BC065245; AAH65245.1; -; mRNA.
DR   CCDS; CCDS42192.1; -.
DR   PIR; PC1219; PC1219.
DR   RefSeq; NP_001352.2; NM_001361.4.
DR   UniGene; Hs.654427; -.
DR   PDB; 1D3G; X-ray; 1.60 A; A=29-395.
DR   PDB; 1D3H; X-ray; 1.80 A; A=29-395.
DR   PDB; 2B0M; X-ray; 2.00 A; A=29-395.
DR   PDB; 2BXV; X-ray; 2.15 A; A=29-395.
DR   PDB; 2FPT; X-ray; 2.40 A; A=29-395.
DR   PDB; 2FPV; X-ray; 1.80 A; A=29-395.
DR   PDB; 2FPY; X-ray; 2.00 A; A=29-395.
DR   PDB; 2FQI; X-ray; 1.95 A; A=29-395.
DR   PDB; 2PRH; X-ray; 2.40 A; A=29-395.
DR   PDB; 2PRL; X-ray; 2.10 A; A=29-395.
DR   PDB; 2PRM; X-ray; 3.00 A; A=29-395.
DR   PDB; 2WV8; X-ray; 1.90 A; A=31-395.
DR   PDB; 3F1Q; X-ray; 2.00 A; A=29-395.
DR   PDB; 3FJ6; X-ray; 1.80 A; A=29-395.
DR   PDB; 3FJL; X-ray; 1.90 A; A=29-395.
DR   PDB; 3G0U; X-ray; 2.00 A; A=29-395.
DR   PDB; 3G0X; X-ray; 1.80 A; A=29-395.
DR   PDB; 3KVJ; X-ray; 1.94 A; A=29-395.
DR   PDB; 3KVK; X-ray; 2.05 A; A=29-395.
DR   PDB; 3KVL; X-ray; 1.85 A; A=29-395.
DR   PDB; 3KVM; X-ray; 2.00 A; A=29-395.
DR   PDB; 3U2O; X-ray; 2.18 A; A=1-395.
DR   PDB; 3W7R; X-ray; 1.68 A; A=29-395.
DR   PDB; 3ZWS; X-ray; 1.60 A; A=29-395.
DR   PDB; 3ZWT; X-ray; 1.55 A; A=29-395.
DR   PDB; 4IGH; X-ray; 1.30 A; A=32-395.
DR   PDB; 4JGD; X-ray; 2.05 A; A=29-395.
DR   PDB; 4JS3; X-ray; 2.00 A; A=29-395.
DR   PDB; 4JTS; X-ray; 2.21 A; A=29-395.
DR   PDB; 4JTT; X-ray; 2.10 A; A=29-395.
DR   PDB; 4JTU; X-ray; 1.90 A; A=29-395.
DR   PDB; 4LS0; X-ray; 2.07 A; A=29-395.
DR   PDB; 4LS1; X-ray; 2.20 A; A=29-395.
DR   PDB; 4LS2; X-ray; 2.27 A; A=29-395.
DR   PDB; 4OQV; X-ray; 1.23 A; A=32-395.
DR   PDB; 4RK8; X-ray; 2.22 A; A=29-395.
DR   PDB; 4RKA; X-ray; 2.71 A; A=29-395.
DR   PDB; 4RLI; X-ray; 2.50 A; A=29-395.
DR   PDB; 4RR4; X-ray; 2.38 A; A=29-395.
DR   PDB; 4YLW; X-ray; 1.79 A; A=29-395.
DR   PDB; 4ZL1; X-ray; 1.86 A; A=29-395.
DR   PDB; 4ZMG; X-ray; 1.90 A; A=29-395.
DR   PDB; 5H2Z; X-ray; 1.58 A; A=29-395.
DR   PDB; 5HIN; X-ray; 1.60 A; A=29-395.
DR   PDB; 5HQE; X-ray; 1.62 A; A=29-395.
DR   PDB; 5K9C; X-ray; 1.66 A; A=29-395.
DR   PDB; 5K9D; X-ray; 1.70 A; A=29-395.
DR   PDB; 5MUT; X-ray; 1.75 A; A=31-395.
DR   PDB; 5MVC; X-ray; 1.85 A; A=29-395.
DR   PDB; 5MVD; X-ray; 1.95 A; A=33-395.
DR   PDBsum; 1D3G; -.
DR   PDBsum; 1D3H; -.
DR   PDBsum; 2B0M; -.
DR   PDBsum; 2BXV; -.
DR   PDBsum; 2FPT; -.
DR   PDBsum; 2FPV; -.
DR   PDBsum; 2FPY; -.
DR   PDBsum; 2FQI; -.
DR   PDBsum; 2PRH; -.
DR   PDBsum; 2PRL; -.
DR   PDBsum; 2PRM; -.
DR   PDBsum; 2WV8; -.
DR   PDBsum; 3F1Q; -.
DR   PDBsum; 3FJ6; -.
DR   PDBsum; 3FJL; -.
DR   PDBsum; 3G0U; -.
DR   PDBsum; 3G0X; -.
DR   PDBsum; 3KVJ; -.
DR   PDBsum; 3KVK; -.
DR   PDBsum; 3KVL; -.
DR   PDBsum; 3KVM; -.
DR   PDBsum; 3U2O; -.
DR   PDBsum; 3W7R; -.
DR   PDBsum; 3ZWS; -.
DR   PDBsum; 3ZWT; -.
DR   PDBsum; 4IGH; -.
DR   PDBsum; 4JGD; -.
DR   PDBsum; 4JS3; -.
DR   PDBsum; 4JTS; -.
DR   PDBsum; 4JTT; -.
DR   PDBsum; 4JTU; -.
DR   PDBsum; 4LS0; -.
DR   PDBsum; 4LS1; -.
DR   PDBsum; 4LS2; -.
DR   PDBsum; 4OQV; -.
DR   PDBsum; 4RK8; -.
DR   PDBsum; 4RKA; -.
DR   PDBsum; 4RLI; -.
DR   PDBsum; 4RR4; -.
DR   PDBsum; 4YLW; -.
DR   PDBsum; 4ZL1; -.
DR   PDBsum; 4ZMG; -.
DR   PDBsum; 5H2Z; -.
DR   PDBsum; 5HIN; -.
DR   PDBsum; 5HQE; -.
DR   PDBsum; 5K9C; -.
DR   PDBsum; 5K9D; -.
DR   PDBsum; 5MUT; -.
DR   PDBsum; 5MVC; -.
DR   PDBsum; 5MVD; -.
DR   ProteinModelPortal; Q02127; -.
DR   SMR; Q02127; -.
DR   BioGrid; 108068; 13.
DR   IntAct; Q02127; 2.
DR   STRING; 9606.ENSP00000219240; -.
DR   BindingDB; Q02127; -.
DR   ChEMBL; CHEMBL1966; -.
DR   DrugBank; DB07561; (2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide.
DR   DrugBank; DB08172; (2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide.
DR   DrugBank; DB08169; (2Z)-N-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide.
DR   DrugBank; DB07443; (2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide.
DR   DrugBank; DB07976; 3-{[(3-FLUORO-3'-METHOXYBIPHENYL-4-YL)AMINO]CARBONYL}THIOPHENE-2-CARBOXYLIC ACID.
DR   DrugBank; DB03805; Antiproliferative Agent A771726.
DR   DrugBank; DB01117; Atovaquone.
DR   DrugBank; DB03480; Brequinar Analog.
DR   DrugBank; DB04147; Lauryl Dimethylamine-N-Oxide.
DR   DrugBank; DB01097; Leflunomide.
DR   DrugBank; DB02262; Orotic Acid.
DR   DrugBank; DB03247; Riboflavin Monophosphate.
DR   DrugBank; DB05125; SC12267.
DR   DrugBank; DB08880; Teriflunomide.
DR   GuidetoPHARMACOLOGY; 2604; -.
DR   iPTMnet; Q02127; -.
DR   PhosphoSitePlus; Q02127; -.
DR   BioMuta; DHODH; -.
DR   DMDM; 56405372; -.
DR   EPD; Q02127; -.
DR   MaxQB; Q02127; -.
DR   PaxDb; Q02127; -.
DR   PeptideAtlas; Q02127; -.
DR   PRIDE; Q02127; -.
DR   TopDownProteomics; Q02127; -.
DR   Ensembl; ENST00000219240; ENSP00000219240; ENSG00000102967.
DR   GeneID; 1723; -.
DR   KEGG; hsa:1723; -.
DR   UCSC; uc002fbp.4; human.
DR   CTD; 1723; -.
DR   DisGeNET; 1723; -.
DR   GeneCards; DHODH; -.
DR   HGNC; HGNC:2867; DHODH.
DR   HPA; HPA010123; -.
DR   HPA; HPA011942; -.
DR   MalaCards; DHODH; -.
DR   MIM; 126064; gene.
DR   MIM; 263750; phenotype.
DR   neXtProt; NX_Q02127; -.
DR   OpenTargets; ENSG00000102967; -.
DR   Orphanet; 246; Postaxial acrofacial dysostosis.
DR   PharmGKB; PA27327; -.
DR   eggNOG; KOG1436; Eukaryota.
DR   eggNOG; COG0167; LUCA.
DR   GeneTree; ENSGT00500000044924; -.
DR   HOGENOM; HOG000225103; -.
DR   HOVERGEN; HBG006898; -.
DR   InParanoid; Q02127; -.
DR   KO; K00254; -.
DR   OMA; ERIKMGA; -.
DR   OrthoDB; EOG091G07JK; -.
DR   PhylomeDB; Q02127; -.
DR   TreeFam; TF105973; -.
DR   BRENDA; 1.3.5.2; 2681.
DR   BRENDA; 1.3.98.1; 2681.
DR   Reactome; R-HSA-500753; Pyrimidine biosynthesis.
DR   SABIO-RK; Q02127; -.
DR   UniPathway; UPA00070; UER00946.
DR   ChiTaRS; DHODH; human.
DR   EvolutionaryTrace; Q02127; -.
DR   GenomeRNAi; 1723; -.
DR   PRO; PR:Q02127; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000102967; -.
DR   CleanEx; HS_DHODH; -.
DR   ExpressionAtlas; Q02127; baseline and differential.
DR   Genevisible; Q02127; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0004152; F:dihydroorotate dehydrogenase activity; TAS:Reactome.
DR   GO; GO:0008144; F:drug binding; IEA:Ensembl.
DR   GO; GO:0010181; F:FMN binding; IEA:Ensembl.
DR   GO; GO:0048039; F:ubiquinone binding; IEA:Ensembl.
DR   GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0044205; P:'de novo' UMP biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0046134; P:pyrimidine nucleoside biosynthetic process; TAS:Reactome.
DR   GO; GO:0090140; P:regulation of mitochondrial fission; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:1903576; P:response to L-arginine; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   CDD; cd04738; DHOD_2_like; 1.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR005720; Dihydroorotate_DH.
DR   InterPro; IPR005719; Dihydroorotate_DH_2.
DR   InterPro; IPR001295; Dihydroorotate_DH_CS.
DR   Pfam; PF01180; DHO_dh; 1.
DR   TIGRFAMs; TIGR01036; pyrD_sub2; 1.
DR   PROSITE; PS00911; DHODEHASE_1; 1.
DR   PROSITE; PS00912; DHODEHASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation; Flavoprotein; FMN;
KW   Membrane; Mitochondrion; Mitochondrion inner membrane; Oxidoreductase;
KW   Polymorphism; Pyrimidine biosynthesis; Reference proteome;
KW   Transit peptide; Transmembrane; Transmembrane helix.
FT   CHAIN         1    395       Dihydroorotate dehydrogenase (quinone),
FT                                mitochondrial.
FT                                /FTId=PRO_0000029884.
FT   TRANSIT       1     10       Mitochondrion; not cleaved.
FT                                {ECO:0000250}.
FT   TOPO_DOM      1     10       Mitochondrial matrix. {ECO:0000250}.
FT   TRANSMEM     11     30       Helical. {ECO:0000250}.
FT   TOPO_DOM     31    395       Mitochondrial intermembrane.
FT                                {ECO:0000250}.
FT   NP_BIND      95     99       FMN. {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   NP_BIND     355    356       FMN. {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   REGION      144    148       Substrate binding.
FT   REGION      211    216       Substrate binding.
FT   REGION      283    284       Substrate binding.
FT   ACT_SITE    214    214       Nucleophile.
FT   BINDING      99     99       Substrate.
FT   BINDING     119    119       FMN. {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   BINDING     180    180       FMN. {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   BINDING     211    211       FMN. {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   BINDING     254    254       FMN. {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   BINDING     282    282       FMN; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   BINDING     305    305       FMN; via amide nitrogen.
FT                                {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   BINDING     334    334       FMN; via amide nitrogen.
FT                                {ECO:0000269|PubMed:10673429,
FT                                ECO:0000269|PubMed:16480261}.
FT   VARIANT       7      7       K -> Q (in dbSNP:rs3213422).
FT                                {ECO:0000269|PubMed:1446837,
FT                                ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_022094.
FT   VARIANT      19     19       G -> E (in POADS; dbSNP:rs267606765).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062412.
FT   VARIANT     135    135       R -> C (in POADS; dbSNP:rs201230446).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062413.
FT   VARIANT     152    152       G -> R (in POADS; dbSNP:rs267606766).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062414.
FT   VARIANT     199    199       R -> C (in POADS; dbSNP:rs267606769).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062415.
FT   VARIANT     202    202       G -> A (in POADS; dbSNP:rs267606767).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062416.
FT   VARIANT     202    202       G -> D (in POADS; dbSNP:rs267606767).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062417.
FT   VARIANT     244    244       R -> W (in POADS; dbSNP:rs267606768).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062418.
FT   VARIANT     284    284       T -> I (in POADS).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062419.
FT   VARIANT     346    346       R -> W (in POADS; dbSNP:rs201947120).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062420.
FT   VARIANT     392    392       D -> G (in POADS; dbSNP:rs779076692).
FT                                {ECO:0000269|PubMed:19915526}.
FT                                /FTId=VAR_062421.
FT   CONFLICT      1      2       MA -> KLP (in Ref. 1; AAA50163).
FT                                {ECO:0000305}.
FT   HELIX        34     39       {ECO:0000244|PDB:4OQV}.
FT   HELIX        41     48       {ECO:0000244|PDB:4OQV}.
FT   HELIX        51     63       {ECO:0000244|PDB:4OQV}.
FT   HELIX        76     78       {ECO:0000244|PDB:4OQV}.
FT   STRAND       80     82       {ECO:0000244|PDB:4OQV}.
FT   STRAND       85     93       {ECO:0000244|PDB:4OQV}.
FT   TURN         95    100       {ECO:0000244|PDB:5K9D}.
FT   STRAND      101    103       {ECO:0000244|PDB:3ZWT}.
FT   HELIX       104    109       {ECO:0000244|PDB:4OQV}.
FT   STRAND      113    120       {ECO:0000244|PDB:4OQV}.
FT   STRAND      133    136       {ECO:0000244|PDB:4OQV}.
FT   HELIX       137    139       {ECO:0000244|PDB:4OQV}.
FT   STRAND      141    144       {ECO:0000244|PDB:4OQV}.
FT   HELIX       153    161       {ECO:0000244|PDB:4OQV}.
FT   HELIX       164    172       {ECO:0000244|PDB:4OQV}.
FT   STRAND      177    181       {ECO:0000244|PDB:4OQV}.
FT   HELIX       190    201       {ECO:0000244|PDB:4OQV}.
FT   HELIX       202    204       {ECO:0000244|PDB:4OQV}.
FT   STRAND      206    212       {ECO:0000244|PDB:4OQV}.
FT   HELIX       220    224       {ECO:0000244|PDB:3ZWT}.
FT   HELIX       226    241       {ECO:0000244|PDB:4OQV}.
FT   HELIX       245    247       {ECO:0000244|PDB:4OQV}.
FT   STRAND      250    255       {ECO:0000244|PDB:4OQV}.
FT   HELIX       261    274       {ECO:0000244|PDB:4OQV}.
FT   STRAND      278    281       {ECO:0000244|PDB:4OQV}.
FT   STRAND      285    287       {ECO:0000244|PDB:5K9C}.
FT   TURN        295    298       {ECO:0000244|PDB:4OQV}.
FT   STRAND      299    305       {ECO:0000244|PDB:4OQV}.
FT   HELIX       306    308       {ECO:0000244|PDB:4OQV}.
FT   HELIX       309    322       {ECO:0000244|PDB:4OQV}.
FT   TURN        323    325       {ECO:0000244|PDB:4OQV}.
FT   STRAND      329    334       {ECO:0000244|PDB:4OQV}.
FT   HELIX       338    347       {ECO:0000244|PDB:4OQV}.
FT   STRAND      349    355       {ECO:0000244|PDB:4OQV}.
FT   HELIX       356    361       {ECO:0000244|PDB:4OQV}.
FT   HELIX       364    379       {ECO:0000244|PDB:4OQV}.
FT   HELIX       385    388       {ECO:0000244|PDB:4OQV}.
FT   HELIX       391    393       {ECO:0000244|PDB:4OQV}.
SQ   SEQUENCE   395 AA;  42867 MW;  072C3169E78C6440 CRC64;
     MAWRHLKKRA QDAVIILGGG GLLFASYLMA TGDERFYAEH LMPTLQGLLD PESAHRLAVR
     FTSLGLLPRA RFQDSDMLEV RVLGHKFRNP VGIAAGFDKH GEAVDGLYKM GFGFVEIGSV
     TPKPQEGNPR PRVFRLPEDQ AVINRYGFNS HGLSVVEHRL RARQQKQAKL TEDGLPLGVN
     LGKNKTSVDA AEDYAEGVRV LGPLADYLVV NVSSPNTAGL RSLQGKAELR RLLTKVLQER
     DGLRRVHRPA VLVKIAPDLT SQDKEDIASV VKELGIDGLI VTNTTVSRPA GLQGALRSET
     GGLSGKPLRD LSTQTIREMY ALTQGRVPII GVGGVSSGQD ALEKIRAGAS LVQLYTALTF
     WGPPVVGKVK RELEALLKEQ GFGGVTDAIG ADHRR
//
